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ABSTRACT
 
Purpose:
 
Cost-utility analyses (CUAs) have become
increasingly popular, although questions persist about
their comparability and credibility. Our objectives were
to: 1) describe the growth and characteristics of CUAs
published in the peer-reviewed literature through 2001; 2)
investigate whether CUA quality has improved over time;
3) examine whether quality varies by the experience of
journals in publishing CUAs, or the source of external
funding for study investigators; and 4) examine changes
in practices in US-based studies following recommenda-
tions of the US Panel on Cost-Effectiveness in Health and
Medicine (USPCEHM). This study updates and expands
our previous work, which examined CUAs through 1997.
Methods: We conducted a systematic search of the Eng-
lish-language medical literature for original CUAs pub-
lished from 1976 through 2001, using Medline and other
databases. Each study was audited independently by two
trained readers, who recorded the methodological and
reporting practices used.
Results: Our review identiﬁed 533 original CUAs. Com-
paring articles published in 1998 to 2001 (n = 305) with
those published in 1976 to 1997 (n = 228), studies
improved in almost all categories, including: clearly pre-
senting the study perspective (73% vs. 52%, P < 0.001);
discounting both costs and quality-adjusted life-years
(82% vs. 73%, P = 0.0115); and reporting incremental
cost-utility ratios (69% vs. 46%, P < 0.001). The propor-
tion of studies disclosing funding sources did not change
(65% vs. 65%, P = 0.939). Adherence to recommended
practices was greater in more experienced journals, and
roughly equal in industry versus non-industry-funded
analyses. The data suggest an impact in methodological
practices used in US-based CUAs in accordance with rec-
ommendations of the USPCEHM.
Conclusions: Adherence to methodological and reporting
practices in published CUAs is improving, although many
studies still omit basic elements. Medical journals, partic-
ularly those with little experience publishing cost-
effectiveness analyses, should adopt and enforce standard
protocols for conducting and reporting CUAs.
Keywords: cost-effectiveness analysis, cost–utility
analysis.
 
Despite the rapid growth in the number of cost-
utility analyses (CUAs) published in the medical lit-
erature, studies have shown that many analyses do
not adhere to recommended practices for conduct-
ing or reporting them [1–3]. In this article we char-
acterize this literature and investigate whether the
methodological and reporting practices used in pub-
lished CUAs have improved over time. Speciﬁcally,
our objectives were to: 1) describe the growth and
characteristics of CUAs published in the peer-
reviewed literature through 2001; 2) investigate
whether quality of CUAs has improved over time;
3) examine whether quality varies by the experience
of journals publishing CUAs, or the source of exter-
nal funding; and 4) examine changes in practices in
US-based studies following recommendations of the
US Panel on Cost-Effectiveness in Health and Med-
icine (USPCEHM).
This study updates a previous analysis,
which examined the quality of CUAs from
1976 to 1997 [3,4]. This update more than
doubles the previous sample size, and also per-
mits an analysis of the impact of the Panel on
Cost-Effectiveness in Health and Medicine,
which published its widely cited recommenda-
tions in 1996 [5,6].
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Data and Methods
 
The Harvard School of Public Health (HSPH) Cost-
Effectiveness Registry
 
Researchers at the Center for Risk Analysis at the
HSPH have developed a comprehensive registry of
cost–utility analyses, which contains detailed
information on CUAs published in the health and
medical literature from 1976 through 2001.
Brieﬂy, we conducted a systematic search for origi-
nal English-language CUAs using Medline, Can-
cerLit, and NLM Gateway through 2001. We
validated our ﬁnal sample against CUAs listed in
the Health Economics Evaluation Database [7],
which identiﬁed a number of additional studies.
The databases were searched for medical subject
headings or text keywords “quality-adjusted,”
“quality-adjusted life-year or QALY,” and “cost-
utility analysis.” We excluded review, editorial, or
methodological articles, as well as cost-effective-
ness analyses that measured health effects in units
other than QALYs, and articles in languages other
than English. A ﬁnal set of 533 articles was
judged ultimately to contain original CUAs and
became part of the registry. More detail on the
search strategy as well as the general development
and contents of the registry is provided elsewhere
[3,4] and on our Web site, http://www.hsph.
harvard.edu/cearegistry.
Each article was scrutinized with the aid of a
standard data auditing form to determine its clarity,
completeness, and quality. Two readers, all with
masters or doctoral degree training in decision anal-
ysis and cost-effectiveness analysis, independently
read and audited each article and then convened for
a consensus audit to resolve discrepancies. Data
were collected on a wide variety of elements related
to the study sponsorship, intervention and compa-
rators under investigation, and the methods used to
estimate and report costs, health effects preference
weights, modeling assumptions, and data limita-
tions. We also included a subjective assessment of
overall study quality on a Likert-type scale from 1
(low) to 7 (high). The score reﬂects readers’ best
judgment about the overall study quality, taking
into account the methodological rigor, the clarity of
the presentation, and the potential value of the
study to decision makers.
Kappa statistics (K) were calculated to meas-
ure the interrater reliability for each item before
consensus. The overall mean K was 0.67 (95%
conﬁdence interval, 0.62–0.72), a rate consid-
ered to represent a “good strength of agree-
ment.” [8]
 
Analysis of Data
 
To describe the growth and characteristics of the
published literature, we examined the number of
CUAs published each year by source of funding
(industry, nonindustry, not reported). We also
describe CUAs by country of study, author afﬁlia-
tion, disease category, and prevention level. Quality
was measured in two ways: by examining the
subjective quality score for each article, and by
measuring an article’s adherence to speciﬁc method-
ological and reporting practices. Methodological
and reporting practices were based on published
recommendations [5,6,9]. We examined eight data
categories: disclosing funding sources; clearly pre-
senting the study perspective; calculating and
reporting incremental ratios; discounting both costs
and QALYs; clearly stating the year for cost esti-
mates; performing sensitivity analyses; conducting
probabilistic sensitivity analyses; and discussing
model validation. The proportion of published
CUAs that adhered to each of these recommended
practices and the mean quality ratings during 1998
to 2001 were compared with the proportion during
1976 to 1997 (the period covered in our previous
data collection effort).
We also compared practices in journals publish-
ing a high-volume (n > 3) versus low-volume (n £ 3)
of CUAs during the study period. Our volume cut-
off of three articles is somewhat arbitrary, although
it provides a convenient threshold, dividing the
sample roughly in half.
Finally, we compared practices in studies funded
by the pharmaceutical and medical device industry
with those funded by governments, foundations, or
other nonindustry sources.
To explore the impact of the Panel on Cost-Effec-
tiveness in Health and Medicine on US-based stud-
ies, we examined three key Panel recommendations:
assuming a societal perspective; using a 3% discount
rate to adjust future costs and health beneﬁts; and
using community-based preference weights as the
source of preferences for QALYs. For this analysis,
we compared two 3-year time periods, 1993–1995
versus 1998–2000, which correspond to years before
and after the Panel recommendations were published
in 1996 [10]. We excluded 1996 and 1997, because
it is unclear whether authors of studies published in
those years would have known about the Panel rec-
ommendations when they submitted their articles to
journals. We focus on the impact for US-based stud-
ies (those conducted primarily by investigators based
in the United States with US policy makers in mind),
because non-US investigators may have followed
guidelines issued in other countries.
 Growth and Quality of CUAs
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Comparisons were made using chi-square and
Student’s 
 
t
 
 tests. All analyses were performed using
Microsoft Excel software. A 
 
P
 
-value of less than
0.05 was considered signiﬁcant for all tests.
 
Results
 
Our review identiﬁed 533 original CUAs. The
number of published CUAs has increased steadily
over time, with somewhat more studies sponsored
by the pharmaceutical and device industry in recent
years (22% in 1998–2001 vs. 14% in 1976–1997,
 
P
 
 = 0.034) (Fig. 1).
Most CUAs have pertained to the United States
(61%), followed by Canada (8%) and the U.K.
(8%) (Table 1). Study investigators have been pre-
dominantly university-afﬁliated (90%). As shown
in Table 1, analyses have covered a wide range of
disease areas, most frequently covering cardiovas-
cular disease (21%), infectious disease (21%), and
cancer (15%). Most CUAs have covered tertiary
care (63%), followed by interventions for second-
ary (22%) and primary prevention (14%).
Numerous journals have published CUAs, most
frequently 
 
Annals of Internal Medicine
 
 (n 
 
=
 
 29),
 
Pharmacoeconomics
 
 (n 
 
=
 
 28), and the 
 
Journal of
the American Medical Association
 
 (n 
 
=
 
 26). Some
journal’s proclivity for publishing CUAs has shifted
over time (Table 2). For example, the 
 
New England
Journal of Medicine
 
, which published nine CUAs
from 1976 to 1997, published only one in the 1998
to 2001 period; in contrast, the 
 
American Journal of
Medicine
 
 published one in the former period and
nine in the latter.
Comparing the 1998 to 2001 period (n 
 
=
 
 305)
with the 1976–1997 period (n 
 
=
 
 228), articles
improved in: clearly presenting the study perspec-
tive (73% vs. 52%, 
 
P
 
 
 
<
 
 0.001); reporting incremen-
tal cost-utility ratios (69% vs. 46%, 
 
P
 
 
 
<
 
 0.001);
discounting both costs and QALYs (82% vs. 73%,
 
P
 
 
 
=
 
 0.011); stating the year of currency for cost esti-
mates (82% vs. 68%, 
 
P
 
 
 
<
 
 0.001), performing sen-
sitivity analyses (93% vs. 89%, 
 
P
 
 
 
=
 
 0.069); and
conducting probabilistic sensitivity analyses (14%
 
Figure 1
 
Growth in published cost–utility analyses, 1976–2001.
*Industry category includes pharmaceutical and medical device com-
pany funded studies.
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Table 1
 
Characteristics of  published cost–utility analyses,
1976–2001 (n 
 
=
 
 533)
 
#
 
%
By country
US
 
323
 
61%
Canada
 
43 8%
 
UK
 
41 8%
 
The Netherlands
 
26 5%
 
Sweden
 
21 4%
 
Australia
 
18 3%
 
Other
 
61
 
11%
By author afﬁliation*
Academic
 
482
 
90%
Health-care organization
 
92
 
17%
Government
 
87
 
16%
Consultant/contract
 
41 8%
 
Pharmaceutical industry
 
36 7%
 
By disease category
Cardiovascular
 
114
 
21%
Infectious diseases
 
105
 
20%
Cancer
 
81
 
15%
Endocrine
 
46 9%
 
Neuropsychiatric
 
46 9%
 
Other
 
141
 
27%
By prevention level
Primary
 
75
 
14%
Secondary
 
115
 
22%
Tertiary
 
336
 
63%
 
*Category is not mutually exclusive.
Source: CUA Registry, Harvard School of  Public Health, http://www.hsph.
harvard.edu/cearegistry.
 
Table 2
 
Journals ranked by number of  published cost–utility
analyses
 
Journal
1976–1997 1998–2001 1976–2001 
# rank # rank # rank
Ann Intern Medicine 11 2 18 2 29 1
Pharmacoeconomics 9 4 19 1 28 2
JAMA 16 1 10 3 26 3
Int J Tech Assess Health
Care
9 4 9 4 18 4
Medical Decis Mak 10 3 3 11 13 5
J Clin Oncol 5 8 6 6 11 6
Am J Medicine 1 15 9 4 10 7
Circulation 6 7 4 10 10 7
N Engl J Medicine 9 4 1 17 10 7
J Vasc Surg 3 14 6 6 9 10
AIDS 1 15 6 6 7 11
J General Int Medicine 4 9 3 11 7 11
Radiology 1 15 6 6 7 11
Stroke 4 9 3 11 7 11
Am J Public Health 4 9 2 14 6 16
BMJ 4 9 2 14 6 16
Health Policy 4 9 2 14 6 16
 
Source: CUA Registry, Harvard School of  Public Health, http://www.hsph.
harvard.edu/cearegistry.
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vs. 2%, 
 
P
 
 
 
<
 
 0.001) (Table 3). The proportion of
studies disclosing funding sources did not change
(65% vs. 65%, 
 
P
 
 
 
=
 
 0.939).
Studies published in “high-volume” journals had
greater adherence to methodological practices than
did studies published in “low-volume” journals in
all categories. In contrast, adherence to protocols
did not vary by the external funding source
(Table 3).
Finally, after publications of the recommenda-
tions of the Panel on Cost-Effectiveness in Health
and Medicine, most US-based studies used a 3%
rather than 5% discount rate (72% in the post-
Panel period vs. 2% before the Panel, 
 
P
 
 
 
<
 
 0.001)
(Table 4). There was also an increase in the use of
community preferences (
 
P
 
 
 
=
 
 0.06) and societal per-
spective (
 
P
 
 
 
=
 
 0.04). There was also a trend toward a
3% discount rate in non-US studies (9% before the
Panel and 24% after, 
 
P
 
 
 
=
 
 0.048), although no
increase in the use of community preferences or
societal perspective.
 
Discussion
 
Our review and critique of the cost–utility literature
through 2001 reveals a dynamic and growing ﬁeld.
CUAs have been published in a wide array of jour-
nals and covered a diverse set of topics.
Our data demonstrate that CUAs are published
not only in specialty methods journals such as 
 
Med-
ical Decision Making and International Journal of
Technology Assessment in Health Care
 
, but also in
mainstream medical journals such as 
 
Annals of
Internal Medicine
 
 and the 
 
Journal of the American
Medical Association
 
 (the cross-journal comparisons
are somewhat unfair because some journals were
unavailable in 1976, e.g., 
 
Pharmacoeconomics
 
 was
launched in 1992, but the general point still holds).
The trend data also suggest an inﬂuence of changes
in editorial policies—in particular, the 
 
New Eng-
land Journal of Medicin
 
e adopted a policy imposing
restrictions for publishing CUAs in its pages in the
mid-1990s [11], and has published few CUAs in
recent years.
Although numerous studies in the past
have raised concerns about the quality of cost-
effectiveness analyses [1,2,12–23], our data provide
some encouraging new evidence that the methodo-
logical rigor of published CUAs is improving.
Adherence to key recommended protocols (e.g.,
clearly stating the study perspective, discounting
future costs and health beneﬁts, reporting incremen-
tal cost–utility ratios) has increased considerable.
The data also suggest an impact of the Panel on
Cost-Effectiveness in Health and Medicine, a trend
suggested by smaller studies of the topic [24].
Although the data could reﬂect natural trends or
other factors (e.g., recommendations of other con-
 
Table 3
 
Comparisons of  methodological and reporting practices in published cost–utility analyses (CUAs)
 
1976–1997
(n 
 
=
 
 228)
1998–2001
(n 
 
=
 
 305)
Low-volume 
journals 
(
 
£
 
3 CUAs 
published)
N 
 
=
 
 233
High-volume 
journals
(
 
>
 
3 CUAs 
published)
N 
 
=
 
 300
Industry-
sponsored 
(n 
 
=
 
 95)
Non-industry  
sponsored 
(n 
 
=
 
 438, including
nonreported)
Disclosed funding sources 65% 65% 57%
 
†
 
70%
 
†
 
– –
Clearly presented study perspective 52%
 
‡
 
73%
 
‡
 
56%
 
‡
 
70%
 
‡
 
68% 63%
Calculated and reported incremental
ratios
46%
 
‡ 69%‡ 53%† 63%† 61% 58%
Discounted both costs and QALYs 73%† 82%† 73%† 82%† 82% 78%
Stated year of  currency for cost
estimates
68%‡ 82%‡ 70%† 81%† 72% 77%
Sensitivity analyses performed 89%* 93%* 86%‡ 95%‡ 91% 91%
Probabilistic sensitivity analyses 2%‡ 14%‡ 6%* 11%* 7% 9%
Discussed model validation/veriﬁcation 13% 14% 10%† 16%† 11% 14%
Quality score on a scale from 1 (low)
to 7 (high): mean (SD)
4.10
  (1.33)
4.25
  (1.28)
 3.74
  (1.26)‡
 4.53
 (1.23)‡
 4.33
  (1.16)
  4.15
 (1.33)
*P-value < 0.1; †P-value < 0.05; ‡P-value < 0.001.
Table 4 Change in practices in US-based cost–utility analy-
ses (CUAs) following the report of  the US Panel on Cost Effec-
tiveness in Health and Medicine*
Before panel
(1993–1995,
n = 48)
After panel 
(1998–2000,
n = 137) P
Community preferences 13% 26% 0.06
Discount rate 3% 2% 72% <0.001
Discount rate 5% 67% 9% <0.001
Societal perspective† 17% 32% 0.04
*The table includes only US-based CUAs published during the years in question
(n = 185). The US Panel on Cost-Effectiveness in Health and Medicine published
its report in late 1996.
†Based on readers’ assessment.
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sensus groups) and not have been caused by the
Panel, the magnitudes of changes seen, particularly
in the use of the 3% discount rate make this seem
unlikely.
To be sure, some concern about the credibility
and comparability of studies lingers. Although over-
all adherence to protocols for conducting and
reporting CUAs has improved, in absolute terms,
there have still been a substantial number of poorer-
quality studies published in recent years. Even in the
1998 to 2001 periods, over one-third of analyses
did not disclose their sources of funding; 31% did
not report incremental ratios; and 27% did not
clearly report the perspective of the analysis.
As we found in earlier analyses [3], our data sug-
gest that a journal’s lack of experience in publishing
CUAs is a key factor in explaining poor adherence
to recommended practices. In contrast, we found no
evidence that pharmaceutical industry funding was
associated with poor practices. These ﬁndings sug-
gest the need for improvement in the peer review
process, where better quality control among journal
editors is warranted, especially among journals with
little experience publishing CUAs.
One way to improve matters is for journals to
follow existing guidelines and checklists for
authors, referees, and editors to improve editorial
management and the quality of articles [13,25,26].
Independent task forces have called for the full dis-
closure of all commercial ties and funding support
and whether any restrictions were placed on
authors, such as control and access to data, publi-
cation rights, and sponsors’ right to review [25].
Other groups have published guidelines calling for
transparency in reporting study methods, as well as
protocols for releasing model software and data for
peer review, and making technical reports available
[6]. Some medical journals have published check-
lists for reviewers and editors to follow [2,13].
Continued monitoring of the ﬁeld is also impor-
tant [27,28]. Research has shown, for example, that
editors and reviewers often fail to adhere to their
own guidelines [13].
Formal scoring systems for evaluating the quality
of health economic analyses may help in terms of
discriminating higher quality studies and providing
an aid to journal editors, and perhaps decision mak-
ers themselves [29]. But more work on their valida-
tion and usefulness is required [30,31]. Observers
draw parallels to the success of the CONSORT and
QUORUM initiatives to improve the methods and
reporting of randomized trials and systematic
reviews [32,33]. Rennie and Luft [33] point out that
efforts to provide a formal systematic structure in
order to reduce selection bias and make studies
more transparent revolutionized the reporting of
reviews.
Beyond that, editors could insist that authors
provide all material on the journal’s Web site them-
selves, as some observers have advocated, so that all
assumptions and data can be reviewed, “like the
discovery process in lawsuits, whereby each side has
access to the underlying data that may be pre-
sented.” [33,34]Concerns about conﬁdentiality and
intellectual property raise challenges, but it is an
area worthy of exploration.
There are a number of limitations to note about
our analysis. An important one is that our investi-
gation is restricted to CUAs, which comprise only
a subset of all economic evaluations—about 8%
according to the Health Economics Evaluation
Database [7].
A second limitation is that our search strategy
was limited to select key words and databases and
may have omitted some studies, although a recent
study has conﬁrmed that Medline is a superior
source for reviews of economic evaluations [35].
Third, other groups of study auditors might score
reporting practices differently, although we note
that our interrater reliability scores between readers
were high. It should be noted that our readers were
not blinded to articles’ journals and authors, which
may have inﬂuenced results. We acknowledge the
lack of blinding as a potential source of bias, par-
ticularly in our subjective assessment scores. We
found that blinding presented a formidable chal-
lenge: even if journal names and authors had been
concealed, our investigators could often identify
them, either by the journal’s distinctive style, by ref-
erences in an article to CUA authors’ past work, or
through readers’ previous familiarity with the arti-
cle itself. In future work, it will be important to con-
sider more carefully ways to blind readers.
Fourth, our comparisons of methodological and
reporting practices imply that each item has equal
weight in judging quality, when in fact some are
likely more important than others; in addition, not
all items are necessarily good measures of quality.
For example, there continues to be debate about
how to best analyze and characterize uncertainty in
cost-effectiveness analyses, as well in other matters
such as whose preferences should be measured in
estimating QALYs [36–38]. In the future, it may be
useful to consider ways to provide differential
weightings according to the importance of items to
an article’s overall quality.
Finally and perhaps most importantly, we did not
judge the merits of clinical or modeling assumptions
Neumann et al.8
made in analyses, only whether protocols for con-
ducting and reporting them were followed. Ulti-
mately, the quality of an analysis is largely a
reﬂection of whether assumptions are reasonable,
not simply whether authors adhered to procedural
guidelines for reporting.
Determining the overall reasonableness of
assumptions or the usefulness of CUAs for decision
makers was beyond the scope of our analysis—and
ultimately may require an effort that goes beyond
traditional peer review. Even with access to all of
the data and models, it required Australian author-
ities 2 weeks to thoroughly review cost-effectiveness
analyses submitted to them by drug companies for
reimbursement consideration, for example [39],
much more time than any reasonable peer reviewer
would spend. In the future, public or private insti-
tutions may emerge to vet economic evaluations for
decision makers.
In conclusion, we found that both the methodo-
logic and reporting practices in published CUAs
have improved over time. It appears that the Panel
on Cost-Effectiveness in Health and Medicine had
an impact on practices, particularly in the United
States. Reassuringly, industry sponsorship does not
appear to be associated with poorer methods or
reporting. It does appear, however, that journals
with little experience publishing CUAs have poorer
adherence to good methodologic practices and
would beneﬁt from increased editorial scrutiny and
adoption of standard protocols for conducting and
reporting CUAs.
The authors are grateful to Richard Chapman, PhD and
John Nadai, MD, for assistance in data collection, and
Richa Pande, MD, MPH, for statistical analysis and help-
ful comments.
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